Open AccessEvaluation of lytic activity of staphylococcal bacteriophage Sb‐1 against freshly isolated clinical pathogens
Author(s) -
Kvachadze Leila,
Balarjishvili Nana,
Meskhi Tamila,
Tevdoradze Ekaterine,
Skhirtladze Natia,
Pataridze Tamila,
Adamia Revaz,
Topuria Temur,
Kutter Elizabeth,
Rohde Christine,
Kutateladze Mzia
Publication year - 2011
Publication title -
microbial biotechnology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.287
H-Index - 74
ISSN - 1751-7915
DOI - 10.1111/j.1751-7915.2011.00259.x
Subject(s) - lytic cycle , bacteriophage , staphylococcus aureus , microbiology and biotechnology , phage therapy , virulence , antibiotics , virology , antibiotic resistance , phage typing , biology , staphylococcal infections , drug resistance , bacteria , virus , gene , serotype , escherichia coli , genetics
Summary In recent decades the increase in antibiotic‐resistant bacterial strains has become a serious threat to the treatment of infectious diseases. Drug resistance of Staphylococcus aureus has become a major problem in hospitals of many countries, including developed ones. Today the interest in alternative remedies to antibiotics, including bacteriophage treatment, is gaining new ground. Here, we describe the staphylococcal bacteriophage Sb‐1 – a key component of therapeutic phage preparation that was successfully used against staphylococcal infections during many years in the Former Soviet Union. This phage still reveals a high spectrum of lytic activity in vitro against freshly isolated, genetically different clinical samples (including methicillin‐resistant S. aureus ) obtained from the local hospitals, as well as the clinics from different geographical areas. The sequence analyses of phage genome showed absence of bacterial virulence genes. A case report describes a promising clinical response after phage application in patient with cystic fibrosis and indicates the efficacy of usage of Sb‐1 phage against various staphylococcal infections.